New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published

 New Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines published

• 19th Invitation for Expression of Interest (EOI) to manufacturers of antimalarial medicines
   

1)  Additions:

Under section: 2. Artemisinin-based fixed dose combination oral paediatric formulations, preferably dispersible

• Dihydroartemisinin/Piperaquine, phosphate, tablet 20 mg/160 mg (scored) - addition of (scored)

Under section: 5. Other antimalarial medicines

• Sulfadoxine/Pyrimethamine tablets 250 mg/12.5 mg (preferably dispersible for paediatric use); 500 mg/25 mg (scored) - addition of (preferably dispersible for paediatric use)

2)  Deletions:

Under section: 3. Artemisinin-based single-ingredient formulations

• Artesunate, tablet 25 mg; 50 mg; 100 mg - deleted with corresponding footnote

Under section: 5. Other antimalarial medicines

• Primaquine base 3.75 mg tablets (preferably dispersible for paediatric use) - deleted